Vertex Pharmaceuticals’ (VRTX) “Outperform” Rating Reaffirmed at William Blair
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
ORG Partners LLC Has $41,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
clinicaladvisor.com13d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Yahoo Finance23d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...
MedPage Today26d
Next-in-Class Once-Daily Pill Approved for Cystic Fibrosis
Eligible patients must have at least one mutation in F508del or another responsive mutation in the CFTR gene. Of note, the CFTR modulator carries a boxed warning over the risk of drug-induced ...
Monthly Prescribing Reference19d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
An additional 94 non-F508del CFTR mutations and a boxed warning on liver injury and liver failure were included in the updated prescribing information. 1507_1515del9, 2183A→G, A1067P ...
FiercePharma23d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
The Business Journals22d
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.